DE602004025689D1 - Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren - Google Patents

Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren

Info

Publication number
DE602004025689D1
DE602004025689D1 DE602004025689T DE602004025689T DE602004025689D1 DE 602004025689 D1 DE602004025689 D1 DE 602004025689D1 DE 602004025689 T DE602004025689 T DE 602004025689T DE 602004025689 T DE602004025689 T DE 602004025689T DE 602004025689 D1 DE602004025689 D1 DE 602004025689D1
Authority
DE
Germany
Prior art keywords
coronavires
infections
prevention
treatment
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004025689T
Other languages
English (en)
Inventor
Abelardo Silva
John W Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequoia Pharmaceuticals Inc
Original Assignee
Sequoia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequoia Pharmaceuticals Inc filed Critical Sequoia Pharmaceuticals Inc
Publication of DE602004025689D1 publication Critical patent/DE602004025689D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602004025689T 2003-04-28 2004-04-28 Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren Expired - Fee Related DE602004025689D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46578203P 2003-04-28 2003-04-28
US46643203P 2003-04-30 2003-04-30
PCT/US2004/012962 WO2005032453A2 (en) 2003-04-28 2004-04-28 Antiviral agents for the treatment, control and prevention of infections by coronaviruses

Publications (1)

Publication Number Publication Date
DE602004025689D1 true DE602004025689D1 (de) 2010-04-08

Family

ID=34425768

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004025689T Expired - Fee Related DE602004025689D1 (de) 2003-04-28 2004-04-28 Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren

Country Status (9)

Country Link
US (2) US7151163B2 (de)
EP (1) EP1620061B1 (de)
JP (1) JP2007526213A (de)
KR (1) KR20060041163A (de)
AT (1) ATE458750T1 (de)
AU (1) AU2004277370A1 (de)
CA (1) CA2524209A1 (de)
DE (1) DE602004025689D1 (de)
WO (1) WO2005032453A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013347797A1 (en) * 2012-11-25 2015-07-02 The Regents Of The University Of California Peptides that stimulate subcutaneous adipogenesis
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
EP4121025A4 (de) 2020-03-17 2024-03-27 Enzo Biochem, Inc. Verbindungen zur modulierung des sphingosin-signalwegs zur behandlung von coronavirus-infektionen
AU2021271330A1 (en) * 2020-05-14 2022-12-15 Palani Llc A fatty acid based composition for treatment and/or prevention of enveloped-virus related infections
WO2022026921A1 (en) * 2020-07-30 2022-02-03 Repertoire Immune Medicines, Inc. Identification and use of t cell epitopes in designing diagnostic and therapeutic approaches for covid-19
JP7302795B2 (ja) * 2020-09-09 2023-07-04 株式会社バイオインテグレンス コロナウイルスの感染防御方法
CN112300290B (zh) * 2020-09-30 2022-04-01 北京康乐卫士生物技术股份有限公司 一种使用乳头瘤病毒类病毒颗粒递呈抗原的新型冠状病毒多肽疫苗
US11479582B2 (en) 2020-10-16 2022-10-25 King Faisal University Anti-SARS-CoV-2 fusion peptides
EP4370681A1 (de) * 2021-07-16 2024-05-22 Joint Stock Company "Biocad" Auf influenzavirus basierendes isoliertes rekombinantes virus

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3431194A (en) 1966-10-14 1969-03-04 Exxon Research Engineering Co Process for lowering the pour point of a middle distillate
US4080397A (en) 1976-07-09 1978-03-21 Mobile Oil Corporation Method for upgrading synthetic oils boiling above gasoline boiling material
DE3870429D1 (de) 1987-12-18 1992-05-27 Exxon Research Engineering Co Verfahren zur hydroisomerisierung von fischer-tropsch-wachs zur herstellung von schmieroel.
US5387348A (en) * 1990-11-09 1995-02-07 Ebara Corporation Method of mixed-bed filtration and demineralization with ion-exchange resins
CA2104158C (en) 1992-08-18 2005-11-15 Jacobus Eilers Process for the preparation of hydrocarbon fuels
US5378348A (en) 1993-07-22 1995-01-03 Exxon Research And Engineering Company Distillate fuel production from Fischer-Tropsch wax
US5888376A (en) 1996-08-23 1999-03-30 Exxon Research And Engineering Co. Conversion of fischer-tropsch light oil to jet fuel by countercurrent processing
FR2799202B1 (fr) 1999-09-30 2002-04-26 Inst Francais Du Petrole Procede de production d'essences a indice d'octane ameliore
WO2001034186A1 (en) * 1999-11-12 2001-05-17 Lehrer Samuel B Compositions and methods for modifying an immune response against tropomyosin
PL207933B1 (pl) * 2001-05-17 2011-02-28 Stichting Tech Wetenschapp Wyizolowana lub zrekombinowana replikatywna cząsteczka podobna do koronawirusa, kompozycja zawierająca tą cząsteczkę do zastosowania terapeutycznego, do zastosowania jako immunogen lub szczepionka i do zastosowania diagnostycznego
US7460960B2 (en) * 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
EP1613650A2 (de) * 2003-04-08 2006-01-11 CoroNovative B.V. Schweres acutes respiratorisches syndrom (sars) verursachendes coronavirus
US20040229219A1 (en) * 2003-04-30 2004-11-18 Gallaher William R. Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)
CA2441677A1 (en) * 2003-05-09 2004-11-09 Adaltis Inc. Peptides and mixtures thereof for detecting antibodies to severe acute respiratory syndrome-associated coronavirus

Also Published As

Publication number Publication date
EP1620061A4 (de) 2007-09-12
US20060258577A1 (en) 2006-11-16
WO2005032453A3 (en) 2007-02-08
US20070185027A1 (en) 2007-08-09
JP2007526213A (ja) 2007-09-13
KR20060041163A (ko) 2006-05-11
US7151163B2 (en) 2006-12-19
ATE458750T1 (de) 2010-03-15
EP1620061B1 (de) 2010-02-24
AU2004277370A1 (en) 2005-04-14
EP1620061A2 (de) 2006-02-01
CA2524209A1 (en) 2005-04-14
WO2005032453A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
MY151199A (en) Substituted diphenyl heterocycles useful for treating hcv infection
DK1377314T3 (da) Monoklonale antistoffer mod CLFA-proteinet og fremgangsmåder til anvendelse i behandling eller forebyggelse af infektioner
DK1556021T3 (da) Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger
BRPI0509140A (pt) processos para o tratamento de infecção por hiv
EA200701297A1 (ru) Соединения пиридазинона
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
BRPI0415883A (pt) compostos e composições de nucleosìdeo para o tratamento de infecções virais
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE427116T1 (de) Behandlung von bakteriellen infektionen
BRPI0413234A (pt) derivados de imidazola bicìclica contra flaviviridae
ATE409181T1 (de) Proteomimetische verbindungen und verfahren
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
CY1107439T1 (el) Μεθοδοι προληψης και θεραπειας μολυνσης απο ιο του γενους flavivirus σε ζωα
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
DK1763339T3 (da) Orale antimikrobielle farmaceutiske præparater
NO20053348L (no) Farmasoytisk sammensetning for behandling av virusangrep.
DE112004000961D2 (de) Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
DE602004025689D1 (de) Antivirale mittel zur behandlung, kontrolle und prävention von infektionen durch coronaviren
DE602005007471D1 (de) Satraplatin zur behandlung von resistenten oder refrkatären tumoren
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
BRPI0410967A (pt) compostos, composições e seus usos para o tratamento de infecções por vìrus da famìlia flaviviridae
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee